Tabatabaee, AliyeNafari, BehjatFarhang, ArminHariri, AmiraliKhosravi, ArezooZarrabi, AliMirian, Mina2024-05-192024-05-1920230167-76591573-7233https://doi.org10.1007/s10555-023-10154-7https://hdl.handle.net/20.500.12713/5677This comprehensive review explores vimentin as a pivotal therapeutic target in cancer treatment, with a primary focus on mitigating metastasis and overcoming drug resistance. Vimentin, a key player in cancer progression, is intricately involved in processes such as epithelial-to-mesenchymal transition (EMT) and resistance mechanisms to standard cancer therapies. The review delves into diverse vimentin inhibition strategies. Precision tools, including antibodies and nanobodies, selectively neutralize vimentin's pro-tumorigenic effects. DNA and RNA aptamers disrupt vimentin-associated signaling pathways through their adaptable binding properties. Innovative approaches, such as vimentin-targeted vaccines and microRNAs (miRNAs), harness the immune system and post-transcriptional regulation to combat vimentin-expressing cancer cells. By dissecting vimentin inhibition strategies across these categories, this review provides a comprehensive overview of anti-vimentin therapeutics in cancer treatment. It underscores the growing recognition of vimentin as a pivotal therapeutic target in cancer and presents a diverse array of inhibitors, including antibodies, nanobodies, DNA and RNA aptamers, vaccines, and miRNAs. These multifaceted approaches hold substantial promise for tackling metastasis and overcoming drug resistance, collectively presenting new avenues for enhanced cancer therapy.eninfo:eu-repo/semantics/closedAccessVimentinMetastasisPlasticityDrug ResistanceInhibitorEmtReview Article38012357WOS:0011071284000012-s2.0-85178355176N/A10.1007/s10555-023-10154-7Q1